Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts